GRI Bio reports developments from its clinical-stage biopharmaceutical pipeline of Natural Killer T cell modulators for inflammatory, fibrotic and autoimmune diseases. Recurring updates center on GRI-0621, an RARβγ agonist being developed as an oral therapy for idiopathic pulmonary fibrosis, including Phase 2a clinical, biomarker, immune-profiling and gene-expression data.
The company also issues news on GRI-0803 and other type 2 diverse NKT agonist programs, patents covering dNKT agonists and novel compound compositions, its proprietary compound library, financial results, equity financings, Nasdaq compliance matters, reverse stock split actions and conference participation.
GRI Bio (NASDAQ: GRI) has received authorization from the Australian MHRA and HREC to initiate a Phase 2a biomarker study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) in Australia. This expands the global reach of their clinical development and is expected to accelerate enrollment. The company remains on track to report interim data in Q4 2024 and topline data in Q1 2025.
The study will enroll approximately 36 subjects with IPF, randomized in a 2:1 ratio for GRI-0621 4.5mg or placebo, administered orally once daily for 12 weeks. The primary endpoint is safety and tolerability, with secondary endpoints including changes in serum biomarkers, pharmacokinetics, and pharmacodynamic activity. The study also includes a sub-study examining NKT cells in bronchoalveolar lavage fluid.
GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic, and autoimmune diseases, has announced its participation in a Virtual Investor CEO Connect segment. The event is scheduled for October 2, 2024, at 12:00 PM ET.
CEO Marc Hertz, PhD, will deliver a brief presentation followed by an interactive Q&A session. Investors can submit questions live during the event or in advance via email to GRI@jtcir.com. The presentation will be available as a live video webcast on the company's website, with a replay accessible for 90 days after the event.
GRI Bio (NASDAQ: GRI) recently participated in a Virtual Investor KOL Connect segment, featuring Albert Agro, PhD, CMO of GRI Bio, and Dr. Helen Parfrey, a prominent expert in Idiopathic Pulmonary Fibrosis (IPF). The discussion focused on IPF, current patient experiences, and GRI Bio's lead program, GRI-0621. This small molecule RAR-βɣ dual agonist inhibits iNKT cell activity and has shown promise in improving fibrosis and inflammation markers in preliminary trials.
GRI Bio is advancing GRI-0621 through a Phase 2a biomarker study, with interim data expected in Q4 2024 and topline data in Q1 2025. The company aims to address the limitations of current IPF treatments, which have significant side effects and impact on overall survival. GRI-0621 represents a potential new therapeutic approach to halt disease progression in fibrotic diseases like IPF.
GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic, and autoimmune diseases, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place from September 9-11, 2024 in New York, NY.
CEO Marc Hertz, PhD, will deliver a presentation and engage in one-on-one meetings with qualified investors. A video webcast of the presentation will be available on-demand starting September 9, 2024, at 7:00 AM ET for registered attendees. The webcast will also be accessible on the company's website and archived for 90 days post-event.
GRI Bio (NASDAQ: GRI), a biotech company developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic, and autoimmune diseases, has announced its participation in the 2024 European Respiratory Congress (ERS) in Vienna, Austria. The company's abstract has been accepted for a poster presentation on September 9, 2024.
The presentation, titled 'Type 1 Invariant Natural Killer T Cells Drive Lung Fibrosis', will be delivered by Emily Calamita from Dr. Adam Byrne's laboratory at Imperial College London. This research aligns with GRI Bio's focus on NKT cell modulators and their potential applications in treating respiratory conditions.
The poster session, scheduled from 12:30 - 2:00 PM CEST, falls under the category of 'Novel Insights in the Pathogenesis of Pulmonary Fibrosis', highlighting the company's contributions to advancing understanding in this field.
GRI Bio (NASDAQ: GRI) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
1. Phase 2a biomarker study of GRI-0621 for Idiopathic Pulmonary Fibrosis (IPF) on track with interim data expected in Q4 2024 and topline data in Q1 2025.
2. Net loss of $2.4 million for Q2 2024.
3. R&D expenses at $0.9 million, G&A expenses at $1.4 million.
4. Cash and equivalents of $6.4 million as of June 30, 2024.
5. Closed a public offering with gross proceeds of $4.0 million.
6. Cash runway expected into Q1 2025.
7. Expanded IP protection with Korean patent grant.
8. Presented positive preclinical data for GRI-0621 in IPF and GRI-0803 for systemic lupus erythematosus.
GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic, and autoimmune diseases, has announced its participation in the Virtual Investor Lunch Break Series on July 17, 2024, at 12:00 PM ET. The event will feature a corporate overview and business outlook presented by CEO Marc Hertz, PhD.
Investors can join the live video webcast and participate in a Q&A session. The presentation will be available on the company's website, with a replay accessible for 90 days following the event. This presentation offers an opportunity for stakeholders to gain insights into GRI Bio's innovative pipeline and future prospects.
GRI Bio (NASDAQ: GRI), a biotechnology firm specializing in NKT cell modulators for inflammatory, fibrotic, and autoimmune diseases, has released a Virtual Investor 'What This Means' segment. CEO Marc Hertz, PhD, emphasizes the significance of interim data from their Phase 2a biomarker study on Idiopathic Pulmonary Fibrosis (IPF) for the GRI-0621 program. This segment delves into the implications of the data for GRI Bio's ongoing IPF study. The video is available for viewing on the Virtual Investor website.
GRI Bio, a biotechnology company, has regained compliance with Nasdaq listing standards as of July 2, 2024. The company, known for its Natural Killer T cell modulators targeting inflammatory, fibrotic, and autoimmune diseases, received a notice from Nasdaq indicating that it meets all requirements for continued listing on the Nasdaq Capital Market. Consequently, the scheduled hearing before the Hearings Panel has been canceled. CEO Marc Hertz expressed excitement over this development and emphasized the company's focus on advancing their core business objectives.
GRI Bio has published promising preclinical data for its lead program, GRI-0621, in the American Journal of Respiratory and Critical Care Medicine. The study shows that inhibiting type 1 invariant NKT (iNKT) cell activity can reduce fibrosis and inflammation in a mouse model of Idiopathic Pulmonary Fibrosis (IPF). Compared to controls, GRI-0621-treated mice exhibited significant improvements in lung histology, decreased fibrosis scores, and reduced lung inflammation. The company is advancing a Phase 2a biomarker study of GRI-0621 in IPF patients, with interim results expected in Q3 2024 and topline data in Q4 2024.